<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665117</url>
  </required_header>
  <id_info>
    <org_study_id>STU 092015-058</org_study_id>
    <nct_id>NCT02665117</nct_id>
  </id_info>
  <brief_title>Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate</brief_title>
  <official_title>Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chlorthalidone (CTD) may produce various metabolic disturbances, including hypokalemia,
      activation of Renin-Angiotensin- Aldosterone (RAA) system, oxidative stress, dyslipidemia,
      Fibroblast growth factor 23 (FGF23) synthesis, and magnesium depletion. These factors may
      interact with each other to contribute to the development of insulin resistances and
      metabolic syndrome. Smaller studies have suggested that Potassium magnesium Citrate (KMgCit)
      can ameliorate CTD- induced metabolic side effects independent of correction of hypokalemia.
      This study will tests if KMgCit ameliorates CTD induced metabolic effects independent of
      correction of hypokalemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CTD- induced metabolic side effects were though to be dependent on hypokalemia, but
      subsequent studies suggested that CTD - induced side effects were independent from
      hypokalemia. On the other hand, magnesium depletion has been linked to increased
      Renin-Angiotensin- Aldosterone (RAA) system, the development of metabolic syndrome and
      insulin resistance with magnesium supplementation ameliorating these effects.

      Participants will participate in a double-blinded, parallel design study. After baseline
      evaluation participants will take Chlorthalidone (CTD) alone for 2-3 weeks. They will then be
      randomized to two equal groups to take KMgCit powder or Potassium Chloride (KCl) powder along
      with CTD for 4 months.

      We speculate that Mg depletion is responsible for hepatic fat deposition, which then produces
      insulin resistance. Co-administration of KMgCit powder would avert magnesium (Mg) depletion,
      block hepatic fat deposition by restoring normal Mg status and direct intestinal binding of
      fat, thereby ameliorating insulin resistance. To test this hypothesis, we shall quantitate
      muscle Mg status and hepatic fat content by magnetic resonance spectroscopy (MRS) before and
      after KMgCit. Change in fasting glucose, insulin resistance, serum potassium, FGF23, and
      aldosterone will be compared between KCL and KMgCit groups after 4 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fasting plasma glucose</measure>
    <time_frame>4 months</time_frame>
    <description>Will be measured from venous blood sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic fat</measure>
    <time_frame>4 months</time_frame>
    <description>Will be measured using hepatic magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle magnesium content</measure>
    <time_frame>4 months</time_frame>
    <description>Will be measured using magnetic resonance imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Aldosterone</measure>
    <time_frame>4 months</time_frame>
    <description>Will be measured from serum sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FGF23</measure>
    <time_frame>4 months</time_frame>
    <description>Will be measured from serum sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Isoprostanes</measure>
    <time_frame>4 months</time_frame>
    <description>Will be measured before and after treatment regimen containing potassium salt.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>KMgCit + Chlorthalidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KCl + Chlorthalidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Magnesium Citrate (KMgCit)</intervention_name>
    <description>KMgCit will be administer for 4 months with chlorthalidone.</description>
    <arm_group_label>KMgCit + Chlorthalidone</arm_group_label>
    <other_name>KMgCit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Chloride (KCl)</intervention_name>
    <description>KCl will be administer for 4 months with chlorthalidone.</description>
    <arm_group_label>KCl + Chlorthalidone</arm_group_label>
    <other_name>KCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.</description>
    <arm_group_label>KMgCit + Chlorthalidone</arm_group_label>
    <arm_group_label>KCl + Chlorthalidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Treated or untreated stage I hypertension

        Exclusion Criteria:

          -  Diabetes mellitus,

          -  Renal impairment (serum creatinine &gt; 1.4 mg/dL),

          -  Any heart diseases such as congestive heart failure, sustained arrhythmia, or coronary
             heart disease,

          -  Chronic regular NSAID use,

          -  Allergy to thiazide diuretics,

          -  Gastro-esophageal reflux disease (GERD) requiring treatment with acid reducing agents
             or antacid more than once a week,

          -  Esophageal-gastric ulcer or history of gastrointestinal bleeding,

          -  Chronic diarrhea, vomiting,

          -  Excessive sweating,

          -  Unprovoked hypokalemia (serum K &lt; 3.5 mmol/L) or hyperkalemia (serum K &gt; 5.3 mmol/L),

          -  Abnormal liver function test (Aspartate transaminase (AST) or Alanine transaminase
             (ALT) above upper limit of normal range),

          -  Subjects on any potassium supplement on a regular basis for any reason, such as
             patients with primary aldosteronism,

          -  Pregnancy,

          -  History of major depression, bipolar disorder, or schizophrenia,

          -  History of substance abuse,

          -  Gout,

          -  Metabolic alkalosis, with serum bicarbonate &gt; 32 meq/L,

          -  Severe dietary salt restriction, less than1/2 spoonful or 50 meq sodium/day.

          -  Claustrophobia

          -  Metal implants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanpen Vongpatanasin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Arbique, DNP</last_name>
    <phone>(214)648-3188</phone>
    <email>debbie.arbique@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Poghni Peri-Okonny, MD</last_name>
    <phone>2146483180</phone>
    <email>poghni.peri-okonny@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Arbique, RN</last_name>
      <phone>214-648-2968</phone>
      <email>debbie.arbique@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <phone>214-648-2103</phone>
      <email>Wanpen.Vongpatanasin@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Arbique, DNP</last_name>
      <phone>214-648-3188</phone>
      <email>debbie.arbique@utsouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ahmed LA. Protective effects of magnesium supplementation on metabolic energy derangements in lipopolysaccharide-induced cardiotoxicity in mice. Eur J Pharmacol. 2012 Nov 5;694(1-3):75-81. doi: 10.1016/j.ejphar.2012.07.036. Epub 2012 Aug 23. Erratum in: Eur J Pharmacol. 2013 Aug 15;714(1-3):526.</citation>
    <PMID>22939974</PMID>
  </reference>
  <reference>
    <citation>Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman WC, Oparil S, Wright JT Jr; Working Group from the National Heart, Lung, and Blood Institute. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008 Jul;52(1):30-6. doi: 10.1161/HYPERTENSIONAHA.108.114389. Epub 2008 May 26. Review.</citation>
    <PMID>18504319</PMID>
  </reference>
  <reference>
    <citation>Guerrero-Romero F, RodrÃ­guez-MorÃ¡n M. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):471-6.</citation>
    <PMID>16598698</PMID>
  </reference>
  <reference>
    <citation>Hata A, Doi Y, Ninomiya T, Mukai N, Hirakawa Y, Hata J, Ozawa M, Uchida K, Shirota T, Kitazono T, Kiyohara Y. Magnesium intake decreases Type 2 diabetes risk through the improvement of insulin resistance and inflammation: the Hisayama Study. Diabet Med. 2013 Dec;30(12):1487-94. doi: 10.1111/dme.12250. Epub 2013 Jun 29.</citation>
    <PMID>23758216</PMID>
  </reference>
  <reference>
    <citation>Koenig K, Padalino P, Alexandrides G, Pak CY. Bioavailability of potassium and magnesium, and citraturic response from potassium-magnesium citrate. J Urol. 1991 Feb;145(2):330-4.</citation>
    <PMID>1988724</PMID>
  </reference>
  <reference>
    <citation>Odvina CV, Mason RP, Pak CY. Prevention of thiazide-induced hypokalemia without magnesium depletion by potassium-magnesium-citrate. Am J Ther. 2006 Mar-Apr;13(2):101-8.</citation>
    <PMID>16645424</PMID>
  </reference>
  <reference>
    <citation>Pak CY. Correction of thiazide-induced hypomagnesemia by potassium-magnesium citrate from review of prior trials. Clin Nephrol. 2000 Oct;54(4):271-5.</citation>
    <PMID>11076102</PMID>
  </reference>
  <reference>
    <citation>Price AL, Lingvay I, Szczepaniak EW, Wiebel J, Victor RG, Szczepaniak LS. The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetol Metab Syndr. 2013 Jul 9;5(1):35. doi: 10.1186/1758-5996-5-35.</citation>
    <PMID>23837919</PMID>
  </reference>
  <reference>
    <citation>Ruml LA, Pak CY. Effect of potassium magnesium citrate on thiazide-induced hypokalemia and magnesium loss. Am J Kidney Dis. 1999 Jul;34(1):107-13.</citation>
    <PMID>10401023</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Wanpen Vongpatanasin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hypokalemia</keyword>
  <keyword>Isoprostanes</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Aldosterone</keyword>
  <keyword>Hepatic fat</keyword>
  <keyword>Muscle Magnesium</keyword>
  <keyword>Liver fat</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

